Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Patient Meeting On Huntington’s, Parkinson’s: No News Is Good News

Executive Summary

Patient-focused drug development meetings address 'soft symptoms' and reimbursement challenges as FDA says it's familiar with most concerns aired by participants.


Related Content

Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
Pfizer Working To Resolve Sickle Cell Drug Hold Up, Dolsten Says
Patient-Focused Drug Development At 10: Where Does It Go From Here?
“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts